TW's Take: our view on NVNO remains that the product will gain approval and substantial sales, but likely remains off investors' radar screens until closer to approval. This PR is more evidence that the company is headed in the...
TW's Take: trial progressing well, results will come early next year which is a modest delay from the original timeline but expected in any trial run during Covid. Overall, very excited for the future here. 57 patients enrolled to...
TW's Take: very positive results sets the stage for approval if the efficacy data comes through as expected. We'll see that data in the first half of 2024. No Deaths or Pulmonary Embolisms Occurring During the 30 Day MAE...
TW's Take: we continue to believe this device is going to succeed and be a big deal for NVNO. IRVINE, CA / July 14, 2023 / enVVeno Medical Corporation (Nasdaq:NVNO) (“enVVeno” or the “Company”), a company setting new standards of care...
TW's Take: data next week is the missing ingredient to finally send NVNO to a decent valuation. Next gen product positions them for eventual billion dollar or more exit. $46.4 million cash and investments on hand sufficient to fund...
TW's Take: outstanding data makes reimbursement and approval highly likely with significant post-approval uptake. I believe this sets the stage for an acquisition within the next 6-12 months. 97% of VenoValve Study Patients Showing Clinical Improvement at Six Months (as...
TW's Take: very positive getting top-notch investors to pay above the market. Financing risk now completely eliminated and the company is exceeding timelines on both products as announced in other press releases today. I remain very bullish on NVNO. Up...
TW's Take: company is exceeding expectations on all fronts. Great news. – 18 VenoValve patients enrolled over the final two months of the study – Surge in VenoValve demand exceeded the enrollment limit – Topline safety and efficacy readout and PMA eligibility...
TW's Take: this product has multi-billion dollar potential and it's great to see the timeline moved up by 6 months. Non-surgical implantation is a game-changer that greatly expands the market. – enVVe development cycle to be reduced by 6 months –...
enVVeno (NVNO) put out a hat trick of press releases today. The news ranged from getting $28 million in a private placement to fundamental updates on both their products. On the surface it all seemed great and the stock...
TW's Take: looking forward to, what I believe will be, outstanding data presented in just over 2 weeks. These results could be the catalyst that propels NVNO towards a greatly improved valuation and likely sparks interest from potential acquirers. IRVINE,...
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank you. ~ This morning enVVeno (NVNO) published the top-line results at the six-month mark of their...
TW's Take: this is a solid hire as his experience dovetails nicely into getting the VenoValve acquired by a larger device company post approval. Appointment bolsters Company’s transition from being a clinical stage to a commercial entity planning for the...
DFC Advisory Services LLC (dba TW Research Group) is an investment adviser. We are also compensated for publishing information on certain companies. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.